Gene editing offers hope for blood disorder patients
NCT ID NCT06024876
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new gene-edited stem cell treatment (CS-101) in 5 people with beta-thalassemia, a severe blood disorder requiring regular blood transfusions. The goal was to see if the treatment is safe and can help patients produce healthy red blood cells, potentially reducing or eliminating the need for transfusions. Participants received their own genetically modified stem cells after a conditioning regimen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- How does a blood disorder drug perform in everyday practice?
- Newborn screening study aims to catch rare diseases at birth
- New stem cell transplant aims to ease severe blood disorders
- Gene-Editing breakthrough offers hope for blood disorder patients
- New stem cell transplant could help sickle cell patients without a perfect donor match
- New pill could help kids with thalassemia fight anemia without transfusions